Sugi Predict

Sugi Predict / Targets / PDCD4

PDCD4

Programmed cell death protein 4 · Q53EL6 · PDCD4 on Sugi Atlas →

2,521 patent compounds predicted against PDCD4, 1,208 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7296014 SCHEMBL7296014 0.47 8/20
SCHEMBL9422969 SCHEMBL9422969 0.42 8/20
SCHEMBL9325205 SCHEMBL9325205 0.41 8/20
SCHEMBL9744998 SCHEMBL9744998 0.40 8/20
SCHEMBL9746833 SCHEMBL9746833 0.40 8/20
SCHEMBL8985089 SCHEMBL8985089 0.40 8/20
SCHEMBL9745710 SCHEMBL9745710 0.39 8/20
SCHEMBL9767002 SCHEMBL9767002 0.39 8/20
SCHEMBL9767030 SCHEMBL9767030 0.39 8/20
SCHEMBL8985069 SCHEMBL8985069 0.39 8/20
SCHEMBL7301468 SCHEMBL7301468 0.39 8/20
SCHEMBL9767329 SCHEMBL9767329 0.39 8/20
SCHEMBL9325019 SCHEMBL9325019 0.38 8/20
SCHEMBL9745643 SCHEMBL9745643 0.38 8/20
SCHEMBL9745763 SCHEMBL9745763 0.38 8/20
SCHEMBL9745768 SCHEMBL9745768 0.37 8/20
SCHEMBL9766934 SCHEMBL9766934 0.37 8/20
SCHEMBL9639282 SCHEMBL9639282 0.36 8/20
SCHEMBL7303345 SCHEMBL7303345 0.35 8/20
SCHEMBL9278935 SCHEMBL9278935 0.47 7/20

Clinical trials — most relevant to PDCD4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) PHASE3COMPLETED
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma PHASE3COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer PHASE2ACTIVE_NOT_RECRUITING
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer PHASE2RECRUITING
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer PHASE2UNKNOWN
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease PHASE2COMPLETED
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) PHASE2COMPLETED
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer PHASE2COMPLETED
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer PHASE2ACTIVE_NOT_RECRUITING
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide PHASE2COMPLETED
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC PHASE2COMPLETED
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer PHASE2COMPLETED
Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma PHASE2COMPLETED
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas PHASE2COMPLETED
Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study PHASE2COMPLETED
Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma PHASE2RECRUITING
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers PHASE1COMPLETED
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer PHASE1COMPLETED
Effect of Severe Trauma on PD1 and Its Legend (PD1/L1) on T Lymphocytes and Correlation With Mortality nanUNKNOWN
Immuno-Oncology Database and Bioregistry nanACTIVE_NOT_RECRUITING
Role of Programmed Death Ligand 1 in Colorectal Cancer nanNOT_YET_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Immune Checkpoint Inhibitors Nephrotoxicity nanRECRUITING
Treatment With Immunological Checkpoint Inhibitors of HIV-infected Subjects With Cancer nanCOMPLETED
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) nanNOT_YET_RECRUITING
Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PDCD4 binder may also engage these)

ProteinNameSimilarity
Q61823 — 1.000 Q61823 →
Q9JID1 — 1.000 Q9JID1 →
Q5R8S3 — 1.000 Q5R8S3 →
Q98TX3 — 1.000 Q98TX3 →
Q8W4Q4 — 0.992 Q8W4Q4 →
O80548 — 0.991 O80548 →
Q94BR1 — 0.990 Q94BR1 →
Q8RW96 — 0.988 Q8RW96 →
Q10LJ0 — 0.987 Q10LJ0 →
Q9STL9 — 0.987 Q9STL9 →
Q9SIU2 — 0.987 Q9SIU2 →
Q6I621 — 0.987 Q6I621 →
Q9MAU3 — 0.987 Q9MAU3 →
Q07205 — 0.985 Q07205 →
B3NU52 — 0.985 B3NU52 →
O82233 — 0.985 O82233 →
Q86T65 — 0.985 Q86T65 →
Q93ZT6 — 0.985 Q93ZT6 →
Q66L58 — 0.984 Q66L58 →
F4IUX6 — 0.984 F4IUX6 →
A4FV68 — 0.984 A4FV68 →
Q16537 — 0.983 Q16537 →
F4JN05 — 0.983 F4JN05 →
B4Q034 — 0.983 B4Q034 →
AP3B1 AP-3 complex subunit beta-1 0.982 landscape →
O00458 — 0.982 O00458 →
Q9ZPV5 — 0.982 Q9ZPV5 →
Q9NQG5 — 0.982 Q9NQG5 →
B3MS75 — 0.982 B3MS75 →
B1AY13 — 0.982 B1AY13 →